Axiom Bio provides an AI-driven translational intelligence platform that predicts human drug toxicity by linking extensive human-relevant experimental data to clinical outcomes. The service offers mechanistic risk assessmentsand early toxicity signals to pharmaceutical scientists, enabling more informed decision‑making and reducing late‑stage drug failures. Revenue is generated through subscription‑based access to the predictive models and risk assessment reports for drug development programs.
Funding
Funding not disclosed
Founders
Product
Problem
Late-stage clinical trial failures due to unexpected drug toxicity, especially liver injury, cost the pharmaceutical industry billions of dollars each year. Traditional animal testing and in‑vitro assays provide limited predictive power for human safety, leading to costly late‑stage attrition and delayed patient access.
Solution
Axiom delivers AI‑driven predictive models that estimate human drug toxicity and exposure risk directly from chemical structure and early‑stage assay data. By training on the world’s largest curated dataset of primary human liver biology, the models achieve higher accuracy and interpretability than conventional animal‑based approaches. Users can query the platform via a web dashboard or programmatic API to obtain quantitative risk scores, mechanistic insights, and exposure predictions early in the discovery pipeline. The service integrates with existing cheminformatics workflows, enabling rapid iteration of compound libraries while reducing the need for expensive animal studies. Secure cloud hosting ensures data confidentiality and compliance with industry standards, and a demo environment allows prospective users to evaluate model performance on their own compounds.
Target Audience
Primary customers are pharmaceutical R&D divisions, biotech firms, and contract research organizations that need early safety assessment of small‑molecule candidates during lead optimization and preclinical development.
Features
- Deep‑learning models trained on a comprehensive human liver transcriptomics and phenotypic dataset, delivering AUC ≈ 0.89 for clinical liver injury prediction
- Interpretable output layers that highlight molecular substructures and pathways driving toxicity risk
- RESTful API and Python SDK for seamless integration with cheminformatics and high‑throughput screening pipelines
- Web‑based dashboard with batch upload, visual risk heatmaps, and exportable PDF/CSV reports
- Built‑in exposure modeling to predict human plasma concentrations from preclinical PK inputs
- Role‑based access control, end‑to‑end encryption, and compliance with data‑security best practices
- Upcoming immunogenicity prediction module expanding safety coverage beyond hepatotoxicity
- Free sandbox demo environment for rapid proof‑of‑concept testing